A Phase 2 interventional study of EYP-1901 and Sham IVT in Nonproliferative Diabetic Retinopathy, sponsored by EyePoint Pharmaceuticals, Inc.. Completed at 36 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-08-15.
Sponsored by EyePoint Pharmaceuticals, Inc. · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 267 studies in Diabetic Retinopathy with a site in United States — 36 open to participants now, 55 under way, 6 of them phase 3. Diabetic Retinopathy · United States.
Among the 267 studies in Diabetic Retinopathy with a site in United States, this one is the 96th largest by enrollment of the 196 interventional ones that give a count, is one of 18 that started in 2022, is one of 52 in phase 2, and was the 204th registered.
779 studies on the registry are indexed under Diabetic Retinopathy; 143 are open to participants now.
Browse Diabetic Retinopathy studies →36 of the 267 studies in Diabetic Retinopathy with a site in United States are open now. Recruiting first, the newest first:
University of Wisconsin, Madison · Sites in United States
Ages 22+
Merck Sharp & Dohme LLC · Sites in United States, Argentina, Israel and 1 more country
Ages 18+
Merck Sharp & Dohme LLC · Sites in United States, Argentina, Australia and 1 more country
Ages 18+
Digital Diagnostics, Inc. · Sites in United States
Ages 22+ · Healthy volunteers
BioAge Labs, Inc. · Sites in United States
Ages 18–75
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 92 Diabetic Retinopathy studies recruiting now, 60 (65%) set no upper age limit and 10 (11%) stop at 75 or younger; 8 take children under 18; 29 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
267 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 37 · Phase 2 64 · Phase 3 35 · Phase 4 20
First in 1992; this study’s year is marked. 18 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 77 is close to the median of 80 across 482 interventional studies indexed under Diabetic Retinopathy.
Median enrollment 72 across the 196 interventional studies, 161 across the 70 observational. Of the 187 that completed or were terminated, 66 (35%) have results posted.
This tab as a report to print or save as PDF → With an account.
114 of 267 have an industry lead sponsor. The 10 most frequent:
EyePoint Pharmaceuticals, Inc. is the lead sponsor of 19 studies on the registry; none are open to participants now.
Of its 11 completed or terminated interventional studies of FDA-regulated products, 8 (73%) have results posted.
EyePoint Pharmaceuticals, Inc. has 2 studies filed under Diabetic Retinopathy — fewer than ten, so there is no comparison to draw.
19 of the studies in Diabetic Retinopathy with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07235085Phase 3Ocular Therapeutix, Inc.A Study to Evaluate the Efficacy and Safety of OTX-TKI (Axitinib Implant) in Participants With Non-Proliferative Diabetic Retinopathy | 2027-03 |
| NCT06191094University of Colorado, DenverPre-operative Vabysmo in Patients With Non-clearing Vitreous Hemorrhage Secondary to Proliferative Diabetic Retinopathy | 2026-12 |
| NCT04008121MediBeaconFeasibility and Safety of MB-102 in Ocular Angiography as Compared to Fluorescein Sodium | 2026-12 |
| NCT07891910Retina Consultants of DelmarvaIopidine to Decrease Intraocular Pressure Rise After Injections | 2026-12-01 |
| NCT05463289Johns Hopkins UniversityACCESS 2: AI for pediatriC diabetiC Eye examS Study 2 | 2026-12-30 |
Add all 19 to your calendar (.ics) → With an account.
Among the 267 studies in Diabetic Retinopathy with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
A prospective, randomized, double-masked study that evaluated the ocular efficacy and safety of two doses of the EYP-1901 intravitreal (IVT) insert compared to sham.
This study evaluated the ocular efficacy and safety of two doses of the EYP-1901 IVT insert compared to sham using a randomized double-masked trial design.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
EYP-1901 2060 ug; single injection
Drug: EYP-1901
EYP-1901 3090 ug; single injection
Drug: EYP-1901
Sham IVT; single injection
Other: Sham IVT
EYP-1901 will be administered to the study eye by a single injection through the pars plana using a pre-loaded applicator with a 22-gauge needle. Each EYP-1901 IVT insert has been designed to deliver vorolanib into the vitreous humor for approximately 6 to 9 months.
Also known as: Vorolanib
Sham injections will be used to maintain masking of investigational EYP-1901 therapy for study subjects.
Percentage of Subjects Improved >=2 Steps From Baseline in the DRSS Score at Week 36
The DRSS used to describe overall retinopathy severity as well as the change in severity over time in the study eye. Severity ranges from level 10 (diabetic retinopathy absent) to level 85 (advanced proliferative diabetic retinopathy (PDR): posterior fundus obscured, or center of macula detached). Here, DRSS describes severity level 47 (moderately severe NPDR) and level 53 (severe NPDR) at Week 36 from baseline.
Time frame: Baseline (Day 1) and Week 36
Percentage of Subjects Improved >=2 Steps From Baseline in the DRSS Score at Week 24 and Week 48
The DRSS used to describe overall retinopathy severity as well as the change in severity over time in the study eye. Severity ranges from level 10 (diabetic retinopathy absent) to level 85 (advanced proliferative diabetic retinopathy (PDR): posterior fundus obscured, or center of macula detached). Here, DRSS describes severity levels 47 (moderately severe NPDR) and 53 (severe NPDR) at Weeks 24 and 48 from baseline.
Time frame: Baseline (Day 1), Week 24, and Week 48
Percentage of Subjects Improved >=2 Steps and >=3 Steps From Baseline in DRSS Score at Weeks 24, 36 and 48
The DRSS used to describe overall retinopathy severity as well as the change in severity over time in the study eye. Severity ranges from level 10 (diabetic retinopathy absent) to level 85 (advanced PDR: posterior fundus obscured, or center of macula detached). Here, DRSS describes severity level 47 (moderately severe NPDR) and level 53 (severe NPDR) at Weeks 24, 36 and 48 from baseline.
Time frame: Baseline (Day 1) and Weeks 24, 36 and 48
Percentage of Subjects Worsened >=2 Steps and >=3 Steps From Baseline in DRSS Score at Weeks 24, 36 and 48
The DRSS used to describe overall retinopathy severity as well as the change in severity over time in the study eye. Severity ranges from level 10 (diabetic retinopathy absent) to level 85 (advanced PDR: posterior fundus obscured, or center of macula detached). Here, DRSS describes severity level 47 (moderately severe NPDR) and level 53 (severe NPDR) at Weeks 24, 36 and 48 from baseline.
Time frame: Baseline (Day 1) and Weeks 24, 36 and 48
Percentage of Subjects Who Developed a Vision-Threatening Complication Due to Diabetic Retinopathy at Weeks 24, 36 and 48
The vision threatening complications in the study eye due to diabetic retinopathy were indicated by the presence of "Vitreous hemorrhage" or the presence of "Tractional retinal detachment" reported on the Ocular Examination - Dilated Ophthalmoscopy CRF (PDR events), and "Neovascularization for the Iris" answered as "Yes" or "Neovascularization for the Angle" answered as "Yes" per the Ocular Examination - Slit Lamp Biomicroscopy CRF (anterior segment neovascularization (ASNV) events).
Time frame: Weeks 24, 36 and 48
Percentage of Subjects Who Developed Center Involved-Diabetic Macular Edema (CI-DME) at Weeks 24, 36 and 48
The CI-DME in the study eye occurred when a treatment emergent adverse event (TEAE) with a mapped preferred term of 'Cystoid macular oedema', 'Diabetic retinal oedema', or 'Macular oedema' occurred in the study eye, in combination with the temporally closest centrally read custom algorithm CST measurement being greater than or equal to 320 microns.
Time frame: Weeks 24, 36 and 48
Time to Develop Any Neovascular Vision Threatening Complication (PDR/ASNV) at Weeks 24, 36 and 48
Time to develop any PDR/ASNV was computed as the date of the first development of PDR/ASNV in the study eye minus the date of study treatment administration plus 1 day, divided by 7 days per week.
Time frame: Weeks 24, 36 and 48
Time to Develop CI-DME Through Weeks 24, 36 and 48
The occurrence of a CI-DME event in the study eye was identified via examination of centrally read custom algorithm CST data and adverse events.
Time frame: Weeks 24, 36 and 48
Percentage of Subjects Who Received Anti-Vascular Endothelial Growth Factor (VEGF) or Additional Standard of Care Intervention Due to Ocular Diabetic Complications at Weeks 24, 36 and 48
Percentage of subjects who received anti-VEGF or additional standard of care intervention due to ocular diabetic complications in the study eye are reported. Anti-VEGF use was identified in reported concomitant medication data.
Time frame: Weeks 24, 36 and 48
Percentage of Subjects Who Received PRP at Weeks 24, 36 and 48
Percentage of subjects who received PRP in the study eye, inclusive of subjects undergoing vitrectomy with endo-laser are reported.
Time frame: Weeks 24, 36 and 48
Area Under the Curve (AUC) for Change From Baseline in BCVA at Weeks 24, 36 and 48
The AUC for change from baseline in BCVA in the study eye were summarized. The AUC through each time point of interest was computed using the trapezoidal rule normalized to months, with a final unit of letters.
Time frame: Weeks 24, 36 and 48
Plasma Concentration of EYP-1901 and X-297 at Weeks 24, 36 and 48
Blood samples were collected at the specific visits for the Pharmacokinetic (PK) analysis of EYP-1901 and its main metabolite concentrations.
Time frame: Weeks 24, 36 and 48
Number of Subjects With Ocular and Non-Ocular TEAEs and Serious TEAEs up to Week 48
An adverse event (AE) is defined as any new untoward medical occurrence or worsening of a pre-existing medical condition in a patient or clinical investigation subject administered an investigational or marketed (medicinal) product and that does not necessarily have a causal relationship with the product. A serious AE is any AE that results in one of the following outcomes: death; life-threatening; requires in-patient hospitalization; results in a persistent or significant disability/incapacity; congenital anomaly/birth defect; other important medical event. The TEAEs are AEs that occur after the first dose of study treatment administration.
Time frame: TEAEs were collected from the study drug administration (Day 1) up to end of the study, approximately 48 weeks.
This Phase 2 prospective, randomized, double-masked study was conducted in adult subjects with NPDR at 25 sites in the United States between 28 September 2022 and 06 May 2024.
| Milestone | Sham Injection | EYP-1901 2060 mcg | EYP-1901 3090 mcg |
|---|---|---|---|
| Started | 26 | 26 | 25 |
| Completed | 21 | 23 | 20 |
| Not completed | 5 | 3 | 5 |
| Withdrew: Adverse event: non-ocular | 0 | 1 | 0 |
| Withdrew: Lost to follow-up | 2 | 1 | 4 |
| Withdrew: Withdrawal by subject | 2 | 0 | 1 |
| Withdrew: Death | 1 | 0 | 0 |
| Withdrew: Other | 0 | 1 | 0 |
The DRSS used to describe overall retinopathy severity as well as the change in severity over time in the study eye. Severity ranges from level 10 (diabetic retinopathy absent) to level 85 (advanced proliferative diabetic retinopathy (PDR): posterior fundus obscured, or center of macula detached). Here, DRSS describes severity level 47 (moderately severe NPDR) and level 53 (severe NPDR) at Week 36 from baseline.
| percentage of subjects | Sham Injection | EYP-1901 2060 mcg | EYP-1901 3090 mcg |
|---|---|---|---|
| Percentage of Subjects Improved >=2 Steps From Baseline in the DRSS Score at Week 36 | 5.0 (0.1 to 24.9) | 0 (0.0 to 16.8) | 4.8 (0.1 to 23.8) |
The DRSS used to describe overall retinopathy severity as well as the change in severity over time in the study eye. Severity ranges from level 10 (diabetic retinopathy absent) to level 85 (advanced proliferative diabetic retinopathy (PDR): posterior fundus obscured, or center of macula detached). Here, DRSS describes severity levels 47 (moderately severe NPDR) and 53 (severe NPDR) at Weeks 24 and 48 from baseline.
| percentage of subjects | Sham Injection (Week 24) | Sham Injection (Week 48) | EYP-1901 2060 mcg (Week 24) | EYP-1901 2060 mcg (Week 48) | EYP-1901 3090 mcg (Week 24) | EYP-1901 3090 mcg (Week 48) |
|---|---|---|---|---|---|---|
| Percentage of Subjects Improved >=2 Steps From Baseline in the DRSS Score at Week 24 and Week 48 | 0 (0.0 to 18.5) | 0 (0.0 to 17.6) | 0 (0.0 to 16.8) | 0 (0.0 to 16.8) | 0 (0.0 to 17.6) | 5.3 (0.1 to 26.0) |
The DRSS used to describe overall retinopathy severity as well as the change in severity over time in the study eye. Severity ranges from level 10 (diabetic retinopathy absent) to level 85 (advanced PDR: posterior fundus obscured, or center of macula detached). Here, DRSS describes severity level 47 (moderately severe NPDR) and level 53 (severe NPDR) at Weeks 24, 36 and 48 from baseline.
| percentage of subjects | Sham Injection | EYP-1901 2060 mcg | EYP-1901 3090 mcg |
|---|---|---|---|
| >=2-step improvement in DRSS: Week 24 | 0 (0.0 to 18.5) | 0 (0.0 to 20.6) | 0 (0.0 to 17.6) |
| >=2-step improvement in DRSS: Week 36 | 5.0 (0.1 to 24.9) | 0 (0.0 to 16.8) | 4.8 (0.1 to 23.8) |
| >=2-step improvement in DRSS: Week 48 | 0 (0.0 to 17.6) | 0 (0.0 to 16.8) | 5.3 (0.1 to 26.0) |
| >=3-step improvement in DRSS: Week 24 | 0 (0.0 to 18.5) | 0 (0.0 to 20.6) | 0 (0.0 to 17.6) |
| >=3-step improvement in DRSS: Week 36 | 0 (0.0 to 16.8) | 0 (0.0 to 16.8) | 0 (0.0 to 16.1) |
| >=3-step improvement in DRSS: Week 48 | 0 (0.0 to 17.6) | 0 (0.0 to 16.8) | 0 (0.0 to 17.6) |
The DRSS used to describe overall retinopathy severity as well as the change in severity over time in the study eye. Severity ranges from level 10 (diabetic retinopathy absent) to level 85 (advanced PDR: posterior fundus obscured, or center of macula detached). Here, DRSS describes severity level 47 (moderately severe NPDR) and level 53 (severe NPDR) at Weeks 24, 36 and 48 from baseline.
| percentage of subjects | Sham Injection | EYP-1901 2060 mcg | EYP-1901 3090 mcg |
|---|---|---|---|
| >=2-step worsening in DRSS: Week 24 | 0 (0.0 to 18.5) | 6.3 (0.2 to 30.2) | 0 (0.0 to 17.6) |
| >=2-step worsening in DRSS: Week 36 | 10.0 (1.2 to 31.7) | 5.0 (0.1 to 24.9) | 0 (0.0 to 16.1) |
| >=2-step worsening in DRSS: Week 48 | 0 (0.0 to 17.6) | 5.0 (0.1 to 24.9) | 0 (0.0 to 17.6) |
| >=3-step worsening in DRSS: Week 24 | 0 (0.0 to 18.5) | 0 (0.0 to 20.6) | 0 (0.0 to 17.6) |
| >=3-step worsening in DRSS: Week 36 | 5.0 (0.1 to 24.9) | 0 (0.0 to 16.8) | 0 (0.0 to 16.1) |
| >=3-step worsening in DRSS: Week 48 | 0 (0.0 to 17.6) | 0 (0.0 to 16.8) | 0 (0.0 to 17.6) |
The vision threatening complications in the study eye due to diabetic retinopathy were indicated by the presence of "Vitreous hemorrhage" or the presence of "Tractional retinal detachment" reported on the Ocular Examination - Dilated Ophthalmoscopy CRF (PDR events), and "Neovascularization for the Iris" answered as "Yes" or "Neovascularization for the Angle" answered as "Yes" per the Ocular Examination - Slit Lamp Biomicroscopy CRF (anterior segment neovascularization (ASNV) events).
| percentage of subjects | Sham Injection | EYP-1901 2060 mcg | EYP-1901 3090 mcg |
|---|---|---|---|
| Week 24 | 0 (0.0 to 13.2) | 3.8 (0.1 to 19.6) | 0 (0.0 to 13.7) |
| Week 36 | 3.8 (0.1 to 19.6) | 3.8 (0.1 to 19.6) | 0 (0.0 to 13.7) |
| Week 48 | 3.8 (0.1 to 19.6) | 3.8 (0.1 to 19.6) | 0 (0.0 to 13.7) |
The CI-DME in the study eye occurred when a treatment emergent adverse event (TEAE) with a mapped preferred term of 'Cystoid macular oedema', 'Diabetic retinal oedema', or 'Macular oedema' occurred in the study eye, in combination with the temporally closest centrally read custom algorithm CST measurement being greater than or equal to 320 microns.
| percentage of subjects | Sham Injection | EYP-1901 2060 mcg | EYP-1901 3090 mcg |
|---|---|---|---|
| Week 24 | 0 (0.0 to 13.2) | 0 (0.0 to 13.2) | 0 (0.0 to 13.7) |
| Week 36 | 0 (0.0 to 13.2) | 0 (0.0 to 13.2) | 4.0 (0.1 to 20.4) |
| Week 48 | 3.8 (0.1 to 19.6) | 0 (0.0 to 13.2) | 8.0 (1.0 to 26.0) |
Time to develop any PDR/ASNV was computed as the date of the first development of PDR/ASNV in the study eye minus the date of study treatment administration plus 1 day, divided by 7 days per week.
| weeks | Sham Injection | EYP-1901 2060 mcg | EYP-1901 3090 mcg |
|---|---|---|---|
| Week 24 | — | NA (NA to NA) | — |
| Week 36 | NA (NA to NA) | NA (NA to NA) | — |
| Week 48 | NA (NA to NA) | NA (NA to NA) | — |
The occurrence of a CI-DME event in the study eye was identified via examination of centrally read custom algorithm CST data and adverse events.
| weeks | Sham Injection | EYP-1901 2060 mcg | EYP-1901 3090 mcg |
|---|---|---|---|
| Week 36 | — | — | NA (NA to NA) |
| Week 48 | NA (NA to NA) | — | NA (NA to NA) |
Percentage of subjects who received anti-VEGF or additional standard of care intervention due to ocular diabetic complications in the study eye are reported. Anti-VEGF use was identified in reported concomitant medication data.
| percentage of subjects | Sham Injection | EYP-1901 2060 mcg | EYP-1901 3090 mcg |
|---|---|---|---|
| Week 24 | 7.7 (0.9 to 25.1) | 7.7 (0.9 to 25.1) | 4.0 (0.1 to 20.4) |
| Week 36 | 7.7 (0.9 to 25.1) | 7.7 (0.9 to 25.1) | 8.0 (1.0 to 26.0) |
| Week 48 | 7.7 (0.9 to 25.1) | 7.7 (0.9 to 25.1) | 12.0 (2.5 to 31.2) |
Percentage of subjects who received PRP in the study eye, inclusive of subjects undergoing vitrectomy with endo-laser are reported.
| percentage of subjects | Sham Injection | EYP-1901 2060 mcg | EYP-1901 3090 mcg |
|---|---|---|---|
| Week 24 | 0 (0.0 to 13.2) | 3.8 (0.1 to 19.6) | 0 (0.0 to 13.7) |
| Week 36 | 0 (0.0 to 13.2) | 3.8 (0.1 to 19.6) | 0 (0.0 to 13.7) |
| Week 48 | 0 (0.0 to 13.2) | 3.8 (0.1 to 19.6) | 0 (0.0 to 13.7) |
The AUC for change from baseline in BCVA in the study eye were summarized. The AUC through each time point of interest was computed using the trapezoidal rule normalized to months, with a final unit of letters.
| letters | Sham Injection | EYP-1901 2060 mcg | EYP-1901 3090 mcg |
|---|---|---|---|
| Week 24 | -0.32 ± 2.969 | -1.58 ± 8.411 | 0.46 ± 4.070 |
| Week 36 | -0.23 ± 3.234 | -1.52 ± 6.819 | 0.03 ± 4.562 |
| Week 48 | -0.38 ± 3.127 | -1.44 ± 6.369 | -0.02 ± 5.311 |
Blood samples were collected at the specific visits for the Pharmacokinetic (PK) analysis of EYP-1901 and its main metabolite concentrations.
| mcg/mL | EYP-1901 2060 mcg | EYP-1901 3090 mcg |
|---|---|---|
| EYP-1901: Week 24 | 11.852 ± 5.6180 | 14.064 ± 5.0654 |
| EYP-1901: Week 36 | 7.660 ± 4.8187 | 9.708 ± 5.5782 |
| EYP-1901: Week 48 | 6.698 ± 3.7642 | 8.194 ± 3.5894 |
| X-297: Week 24 | 0.000 ± 0.0000 | 0.000 ± 0.0000 |
| X-297: Week 36 | 0.999 ± 4.7917 | 0.275 ± 1.2877 |
| X-297: Week 48 | 0.000 ± 0.0000 | 0.657 ± 2.8631 |
An adverse event (AE) is defined as any new untoward medical occurrence or worsening of a pre-existing medical condition in a patient or clinical investigation subject administered an investigational or marketed (medicinal) product and that does not necessarily have a causal relationship with the product. A serious AE is any AE that results in one of the following outcomes: death; life-threatening; requires in-patient hospitalization; results in a persistent or significant disability/incapacity; congenital anomaly/birth defect; other important medical event. The TEAEs are AEs that occur after the first dose of study treatment administration.
| Participants | Sham Injection - Study Eye | Sham Injection - Non-study Eye | Sham Injection - Non-ocular | EYP-1901 2060 mcg - Study Eye | EYP-1901 2060 mcg - Non-study Eye | EYP-1901 2060 mcg - Non-ocular | EYP-1901 3090 mcg - Study Eye | EYP-1901 3090 mcg - Non-study Eye | EYP-1901 3090 mcg - Non-ocular |
|---|---|---|---|---|---|---|---|---|---|
| Any TEAE | 7 | 9 | 15 | 7 | 8 | 16 | 11 | 7 | 12 |
| Any Serious TEAE | 1 | 1 | 2 | 1 | 1 | 7 | 0 | 0 | 1 |
Collected over TEAEs were collected from the study drug administration (Day 1) up to end of the study, approximately 48 weeks.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Sham Injection - Study Eye | 0/26 (0%) | 1/26 (3.8%) | 7/26 (26.9%) |
| Sham Injection - Non-study Eye | 0/26 (0%) | 1/26 (3.8%) | 5/26 (19.2%) |
| Sham Injection - Non-ocular | 1/26 (3.8%) | 2/26 (7.7%) | 9/26 (34.6%) |
| EYP-1901 2060 mcg - Study Eye | 0/26 (0%) | 1/26 (3.8%) | 8/26 (30.8%) |
| EYP-1901 2060 mcg - Non-study Eye | 0/26 (0%) | 1/26 (3.8%) | 8/26 (30.8%) |
| EYP-1901 2060 mcg - Non-ocular | 1/26 (3.8%) | 7/26 (26.9%) | 14/26 (53.8%) |
| EYP-1901 3090 mcg - Study Eye | 0/25 (0%) | 0/25 (0%) | 8/25 (32%) |
| EYP-1901 3090 mcg - Non-study Eye | 0/25 (0%) | 0/25 (0%) | 5/25 (20%) |
| EYP-1901 3090 mcg - Non-ocular | 0/25 (0%) | 1/25 (4%) | 7/25 (28%) |
| Event | Sham Injection - Study Eye | Sham Injection - Non-study Eye | Sham Injection - Non-ocular | EYP-1901 2060 mcg - Study Eye | EYP-1901 2060 mcg - Non-study Eye | EYP-1901 2060 mcg - Non-ocular | EYP-1901 3090 mcg - Study Eye | EYP-1901 3090 mcg - Non-study Eye | EYP-1901 3090 mcg - Non-ocular |
|---|---|---|---|---|---|---|---|---|---|
| SepsisInfections and infestations | 0/26 | 0/26 | 0/26 | 0/26 | 0/26 | 2/26 | 0/25 | 0/25 | 0/25 |
| Cardiac failure congestiveCardiac disorders | 0/26 | 0/26 | 0/26 | 0/26 | 0/26 | 0/26 | 0/25 | 0/25 | 1/25 |
| Urinary tract infectionInfections and infestations | 0/26 | 0/26 | 0/26 | 0/26 | 0/26 | 0/26 | 0/25 | 0/25 | 1/25 |
| Diabetic retinopathyEye disorders | 1/26 | 0/26 | 0/26 | 0/26 | 0/26 | 0/26 | 0/25 | 0/25 | 0/25 |
| Macular oedemaEye disorders | 0/26 | 0/26 | 0/26 | 0/26 | 1/26 | 0/26 | 0/25 | 0/25 | 0/25 |
| Vitreous haemorrhageEye disorders | 0/26 | 0/26 | 0/26 | 1/26 | 0/26 | 0/26 | 0/25 | 0/25 | 0/25 |
| DeathGeneral disorders | 0/26 | 0/26 | 0/26 | 0/26 | 0/26 | 1/26 | 0/25 | 0/25 | 0/25 |
| Oedema peripheralGeneral disorders | 0/26 | 0/26 | 0/26 | 0/26 | 0/26 | 1/26 | 0/25 | 0/25 | 0/25 |
| CellulitisInfections and infestations | 0/26 | 0/26 | 0/26 | 0/26 | 0/26 | 1/26 | 0/25 | 0/25 | 0/25 |
| EndophthalmitisInfections and infestations | 0/26 | 1/26 | 0/26 | 0/26 | 0/26 | 0/26 | 0/25 | 0/25 | 0/25 |
| Event | Sham Injection - Study Eye | Sham Injection - Non-study Eye | Sham Injection - Non-ocular | EYP-1901 2060 mcg - Study Eye | EYP-1901 2060 mcg - Non-study Eye | EYP-1901 2060 mcg - Non-ocular | EYP-1901 3090 mcg - Study Eye | EYP-1901 3090 mcg - Non-study Eye | EYP-1901 3090 mcg - Non-ocular |
|---|---|---|---|---|---|---|---|---|---|
| Diabetic retinal oedemaEye disorders | 4/26 | 0/26 | 0/26 | 2/26 | 0/26 | 0/26 | 2/25 | 0/25 | 0/25 |
| Diabetes mellitusMetabolism and nutrition disorders | 0/26 | 0/26 | 4/26 | 0/26 | 0/26 | 1/26 | 0/25 | 0/25 | 2/25 |
| Diabetic retinopathyEye disorders | 1/26 | 2/26 | 0/26 | 3/26 | 3/26 | 0/26 | 0/25 | 3/25 | 0/25 |
| Macular oedemaEye disorders | 0/26 | 2/26 | 0/26 | 1/26 | 3/26 | 0/26 | 1/25 | 1/25 | 0/25 |
| Glucose urine presentInvestigations | 0/26 | 0/26 | 0/26 | 0/26 | 0/26 | 3/26 | 0/25 | 0/25 | 2/25 |
| Eye painEye disorders | 0/26 | 1/26 | 0/26 | 0/26 | 0/26 | 0/26 | 2/25 | 1/25 | 0/25 |
| Vitreous floatersEye disorders | 0/26 | 0/26 | 0/26 | 0/26 | 0/26 | 0/26 | 2/25 | 0/25 | 0/25 |
| Conjunctival haemorrhageEye disorders | 0/26 | 0/26 | 0/26 | 2/26 | 0/26 | 0/26 | 1/25 | 0/25 | 0/25 |
| Visual acuity reducedEye disorders | 2/26 | 0/26 | 0/26 | 0/26 | 2/26 | 0/26 | 0/25 | 0/25 | 0/25 |
| InfluenzaInfections and infestations | 0/26 | 0/26 | 2/26 | 0/26 | 0/26 | 0/26 | 0/25 | 0/25 | 0/25 |
Full Analysis Set (FAS) included all subjects who received at least 1 dose of study treatment (EYP-1901 or sham).
| Age, Continuous(years) | Sham Injection | EYP-1901 2060 mcg | EYP-1901 3090 mcg | Total |
|---|---|---|---|---|
| Mean | 56.9 ± 11.95 | 56.8 ± 11.79 | 60.2 ± 9.98 | 57.9 ± 11.26 |
| Sex: Female, Male(Participants) | Sham Injection | EYP-1901 2060 mcg | EYP-1901 3090 mcg | Total |
|---|---|---|---|---|
| Female | 13 | 12 | 9 | 34 |
| Male | 13 | 14 | 16 | 43 |
| Ethnicity (NIH/OMB)(Participants) | Sham Injection | EYP-1901 2060 mcg | EYP-1901 3090 mcg | Total |
|---|---|---|---|---|
| Hispanic or Latino | 9 | 8 | 8 | 25 |
| Not Hispanic or Latino | 17 | 16 | 17 | 50 |
| Unknown or Not Reported | 0 | 2 | 0 | 2 |
| Race/Ethnicity, Customized(Participants) | Sham Injection | EYP-1901 2060 mcg | EYP-1901 3090 mcg | Total |
|---|---|---|---|---|
| Asian | 2 | 1 | 1 | 4 |
| Black | 1 | 3 | 5 | 9 |
| White | 21 | 19 | 18 | 58 |
| American Indian or Alaskan Native | 0 | 2 | 0 | 2 |
| Other | 2 | 1 | 1 | 4 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Sep 2022 to primary completion in Feb 2024, 16 months.
Results were first posted in Jul 2025, 1 year 5 months after primary completion.
Of 30 industry-sponsored phase 2 interventional studies under Diabetic Retinopathy, half reached primary completion within 30 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 37. This study's 16 months is below that.
Counting every sponsor, half of 43 studies reached it within 31 months; a quarter within 17 and three quarters within 37.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Vorolanib
EyePoint Pharmaceuticals, Inc.